Statins and risk of cardiovascular disease: Emulating a primary prevention trial in breast cancer survivors
Clicks: 2
ID: 315210
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #309 of 333 articles by views in JNCI Journal of the National Cancer Institute
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Limited evidence is available from randomized trials to guide clinical decision-making for cardiovascular disease (CVD) prevention with statins among women with breast cancer. We leveraged real-world data to estimate the effect of statin therapy vs usual care on the 5-year risk of CVD among breast cancer survivors. Methods We sequentially emulated target trials using the National Cancer Institute-Kaiser Permanente Breast Cancer Survivors Cohort. Women aged 40 − 84 years, diagnosed with stage 0−III breast cancer from 1993 − 2022, without CVD, no statins in the past 6 months, and low-density lipoprotein cholesterol from 100 − 160 mg/dL were included. The outcome was CVD (ischemic heart disease, stroke, and cardiomyopathy/heart failure). We compared statin therapy to usual care (no statins unless indicated) in intention-to-treat and per-protocol analyses. Results Statin initiators were more likely to be older with a higher prevalence of cardiovascular comorbidities. In the intention-to-treat analysis, the 5-year risk difference was 0.3% (95%CI: -0.9,1.5), and risk ratio was 1.04 (95%CI: 0.86,1.25) for statin vs usual care. At 5 years, the proportion adherent to their initial strategy was 48% for statin and 24% for usual care. In the per-protocol analysis, the risk difference was -0.9% (95%CI: -2.9,2.2) and the risk ratio was 0.85 (95%CI: 0.51,1.36) for statin vs usual care. Conclusions Our findings suggest that statin therapy may reduce the risk of CVD for breast cancer survivors, but the estimates are too imprecise for specific recommendations. Future research is needed to understand reasons for statin discontinuation, and opportunities to encourage adherence in this high-risk population.
| Reference Key |
openalex_W7162772118
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Rienna Russo, Miguel A Hernán, Issa J Dahabreh, Eric B Rimm, Lene H S Veiga, Amber N. Hurson, Rochelle E. Curtis, Ruth M. Pfeiffer, Quiera S. Booker, Macy E Corley, Paloma R. Mitra, A Blythe Ryerson, Stacey Honda, Larissa White, Heather Spencer Feigelson, Erin J Aiello Bowles, Véronique L. Roger, Cody Ramin, Ana Barac, Gretchen L. Gierach, Goodarz Danaei, Jacqueline B. Vo |
| Journal | JNCI Journal of the National Cancer Institute |
| Year | 2026 |
| DOI |
10.1093/jnci/djag158
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.